Analysis | Metabolite Name | Measured Value | Units | Gender | Glycemic status | Neuropathy |
---|---|---|---|---|---|---|
Reversed phase NEGATIVE ION MODE | PHENYLALANINE (M-H)- | 86022 | Peak area normalized | male | Pre-diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | PHENYLALANINE (M-H)- | 243313 | Peak area normalized | female | Diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | PHENYLALANINE (M-H)- | 290248 | Peak area normalized | male | Diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | PHENYLALANINE (M-H)- | 300011 | Peak area normalized | female | Diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | PHENYLALANINE (M-H)- | 339427 | Peak area normalized | male | Normoglycemic | Neuropathy |
Reversed phase NEGATIVE ION MODE | PHENYLALANINE (M-H)- | 347748 | Peak area normalized | male | Pre-diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | PHENYLALANINE (M-H)- | 358486 | Peak area normalized | male | Normoglycemic | Neuropathy |
Reversed phase NEGATIVE ION MODE | PHENYLALANINE (M-H)- | 403996 | Peak area normalized | female | Pre-diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | PHENYLALANINE (M-H)- | 404782 | Peak area normalized | female | Pre-diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | PHENYLALANINE (M-H)- | 412255 | Peak area normalized | female | Pre-diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | PHENYLALANINE (M-H)- | 413932 | Peak area normalized | female | Diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | PHENYLALANINE (M-H)- | 416201 | Peak area normalized | male | Pre-diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | PHENYLALANINE (M-H)- | 424849 | Peak area normalized | female | Pre-diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | PHENYLALANINE (M-H)- | 435041 | Peak area normalized | female | Pre-diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | PHENYLALANINE (M-H)- | 451448 | Peak area normalized | male | Pre-diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | PHENYLALANINE (M-H)- | 452116 | Peak area normalized | male | Diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | PHENYLALANINE (M-H)- | 467564 | Peak area normalized | female | Diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | PHENYLALANINE (M-H)- | 469803 | Peak area normalized | female | Pre-diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | PHENYLALANINE (M-H)- | 479883 | Peak area normalized | male | Normoglycemic | no neuropathy |
Reversed phase NEGATIVE ION MODE | PHENYLALANINE (M-H)- | 486272 | Peak area normalized | male | Normoglycemic | no neuropathy |
Reversed phase NEGATIVE ION MODE | PHENYLALANINE (M-H)- | 487070 | Peak area normalized | male | Diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | PHENYLALANINE (M-H)- | 491157 | Peak area normalized | female | Pre-diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | PHENYLALANINE (M-H)- | 514578 | Peak area normalized | male | Diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | PHENYLALANINE (M-H)- | 536632 | Peak area normalized | female | Pre-diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | PHENYLALANINE (M-H)- | 708696 | Peak area normalized | male | Diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | PHENYLALANINE (M-H)- | 734626 | Peak area normalized | male | Diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | PHENYLALANINE (M+H)+ | 20037 | Peak area normalized | female | Pre-diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | PHENYLALANINE (M+H)+ | 25993 | Peak area normalized | female | Pre-diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | PHENYLALANINE (M+H)+ | 27653 | Peak area normalized | female | Pre-diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | PHENYLALANINE (M+H)+ | 32866 | Peak area normalized | male | Pre-diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | PHENYLALANINE (M+H)+ | 37464 | Peak area normalized | female | Pre-diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | PHENYLALANINE (M+H)+ | 41386 | Peak area normalized | male | Diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | PHENYLALANINE (M+H)+ | 42626 | Peak area normalized | male | Normoglycemic | no neuropathy |
Reversed phase POSITIVE ION MODE | PHENYLALANINE (M+H)+ | 42629 | Peak area normalized | male | Diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | PHENYLALANINE (M+H)+ | 42817 | Peak area normalized | male | Normoglycemic | no neuropathy |
Reversed phase POSITIVE ION MODE | PHENYLALANINE (M+H)+ | 44960 | Peak area normalized | male | Diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | PHENYLALANINE (M+H)+ | 47281 | Peak area normalized | female | Diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | PHENYLALANINE (M+H)+ | 49428 | Peak area normalized | male | Normoglycemic | Neuropathy |
Reversed phase POSITIVE ION MODE | PHENYLALANINE (M+H)+ | 54603 | Peak area normalized | male | Diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | PHENYLALANINE (M+H)+ | 64981 | Peak area normalized | male | Diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | PHENYLALANINE (M+H)+ | 66690 | Peak area normalized | female | Pre-diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | PHENYLALANINE (M+H)+ | 67809 | Peak area normalized | female | Diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | PHENYLALANINE (M+H)+ | 83380 | Peak area normalized | male | Diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | PHENYLALANINE (M+H)+ | 87649 | Peak area normalized | male | Pre-diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | PHENYLALANINE (M+H)+ | 96519 | Peak area normalized | female | Diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | PHENYLALANINE (M+H)+ | 116587 | Peak area normalized | female | Pre-diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | PHENYLALANINE (M+H)+ | 493731 | Peak area normalized | male | Pre-diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | PHENYLALANINE (M+H)+ | 501824 | Peak area normalized | male | Pre-diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | PHENYLALANINE (M+H)+ | 502099 | Peak area normalized | female | Pre-diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | PHENYLALANINE (M+H)+ | 524520 | Peak area normalized | female | Diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | PHENYLALANINE (M+H)+ | 606838 | Peak area normalized | female | Pre-diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | PHENYLALANINE (M+H)+ | 705942 | Peak area normalized | male | Normoglycemic | Neuropathy |